Efficacy evaluation | AS-SMP 3 days (N = 435) | AS-SMP 24 hours (N = 418) | AL 3 days (N = 392) |
---|---|---|---|
Cameroon (n) | 85 | 75 | 70 |
ACPR – n (%, 95%CI) | 84 (98.8%,93.6–100.0) | 74 (98.7,92.8–100.0%) | 69 (98.6%,92.3–100.0) |
Mali (n) | 86 | 82 | 85 |
ACPR – n(%, 95%CI) | 86 (100%,95.8–100.0) | 82 (100%,95.6–100.0) | 85 (100%,95.7–100.0) |
Sudan (n) | 84 | 92 | 73 |
ACPR – n(%, 95%CI) | 84 (100%,95.7–100.0) | 92 (100%,96.1–100.0) | 73 (100%,95.1–100.0) |
Rwanda (n) | 180 | 169 | 164 |
ACPR – n(%, 95%CI) | 178 (98.9%,96.0–99.9) | 168 (99.4%,96.7–100.0) | 164 (100%,97.8–100.0) |